InterMune (ITMN) Shares Jump 63% After FDA Announcement

Shares of InterMune, Inc. (Nasdaq: ITMN) surged more than 60% after a panel at the Food and Drug Administration recommended the company's Esbriet for treatment of idiopathic pulmonary fibrosis.

IPF is a rare and deadly lung disease with no existing FDA approved treatments, which affects nearly 200,000 people in the United States and Europe.

Trading of shares of InterMune was halted during the trading day, only to jump more than 60% in after hours trading after the news broke.